CA-PUBMATIC/IAS
PubMatic, the marketing automation software company for publishers, today announced Brand Shield for Buyers, a malware, brand safety and fraud solution that allows media buyers to set customized risk tolerance levels and filter ad impression opportunities according to their preferences. In addition, the company announced that it is working with Integral Ad Science (IAS), a leading solution provider for fraud detection and protection and viewability, that will help media buyers to increase campaign performance by bidding on fraud-free, viewable impressions.
“We’ve seen an increase in the number of buyers that are self-policing the inventory they’re bidding on, making statements about inventory quality with their wallets,” said Rob Jonas, Global Chief Revenue Officer at PubMatic. “At PubMatic, we believe in providing both the premium publishers on our platform and the media buyers bidding on their inventory with a safe environment. Brand Shield for Buyers represents a significant step in combating fraud and suspicious activity, and is the first solution to give buyers a way to set their own individual thresholds for inventory quality so they can truly bid with confidence.”
Fraud and viewability remain ardent concerns for buyers in the digital media and advertising industry. According to a survey conducted by Integral Ad Science, 69% state that media quality is a top priority in their organization, with ad fraud (89%) and viewability (86%) at the top of the list. The concern is validated by Integral Ad Science’s Q1 2015 report indicating that fraud levels at networks and exchanges are 16.5% while viewability is at 41.8%.
“PubMatic’s Brand Shield solution for buyers is a great step towards enabling buyers to take charge over their inventory quality,” said Michael Iantosca, Chief Revenue Officer at Integral Ad Science. “We offer the most advanced technology for both fraud detection and protection as well as viewability measurement, and we are proud to make it available to PubMatic’s clients.”
The benefits of PubMatic’s Brand Shield for Buyers include:
- Increased campaign performance . IAB-based Contextual Categorization, domain-level publisher URL transparency, and the ability to dial buyer risk tolerance levels to filter out ad impressions and improve campaign revenue performance results.
- Buying with confidence . PubMatic’s Brand Safety Scores, which assign safety level scores to publisher inventory, IAB Bot List support, and Inventory Quality filtering providing peace of mind that comes with the knowledge that buyers can avoid bidding on fraudulent impressions.
- Streamlining with a single solution. Solves multiple pain points with one solution by enabling publisher whitelisting through Integral Ad Science, global supply block lists, and in the future access your IAS viewability scores as well.
To find out more about PubMatic’s Brand Shield for Buyers, visit www.pubmatic.com , or schedule a time to meet with the PubMatic team at Cannes Lions this week in the Sean Connery Suite of the Carlton Hotel, located on the main Croisette in Cannes.
About Integral Ad Science
Integral Ad Science is a technology company focused on ensuring safe, quality media environments for online advertisers. Employing the industry’s only media valuation platform, Integral Ad Science evaluates the media environment and establishes a TRAQ Score (True Advertising Quality), a first-of-its-kind, quantifiable measure of media quality that ultimately benefits every media buyer, seller, publisher and trading platform. TRAQ Score supports an advertiser’s ability to plan, execute and target their audience in an environment that reflects their brand image and drives ROI, while simultaneously setting benchmarks for publishers who wish to improve the quality of their content and design to attract premium advertisers. Integral is headquartered in New York with operations in San Francisco, Chicago, London, Berlin, Sydney, Melbourne, Singapore and Paris. Learn more at www.integralads.com .
About PubMatic
PubMatic is the marketing automation software platform company that powers the programmatic advertising strategy of publishers. Through workflow automation, real-time analytics and yield management, PubMatic enables publishers to make smarter, faster decisions that drive revenue and streamline operations. The company’s software solution provides a global roster of comScore publishers with a single view into their advertiser relationships across every screen, every channel and every format. PubMatic was ranked by Deloitte as one of the fastest growing companies in the US Internet sector for the third consecutive year in 2014. The company has offices worldwide, and is headquartered in Redwood City, California.
PubMatic is a registered trademark of PubMatic, Inc. Other trademarks are the property of their respective owners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150623005121/en/
Contact:
Global Press Contact
PubMatic
Paul Cordasco,
646-491-6044
Senior Director, Corporate Communications
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum